George C. Prendergast - Publications

Lankenau Institute for Medical Research 
Cancer Research

204 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Schultz CW, McCarthy GA, Nerwal T, Nevler A, DuHadaway JB, McCoy MD, Jiang W, Brown SZ, Goetz A, Jain A, Calvert VS, Vishwakarma V, Wang D, Preet R, Cassel J, ... ... Prendergast GC, et al. The FDA approved anthelmintic Pyrvinium Pamoate inhibits pancreatic cancer cells in nutrient depleted conditions by targeting the mitochondria. Molecular Cancer Therapeutics. PMID 34413127 DOI: 10.1158/1535-7163.MCT-20-0652  1
2021 Dey S, Mondal A, DuHadaway JB, Sutanto-Ward E, Laury-Kleintop LD, Thomas S, Prendergast GC, Mandik-Nayak L, Muller AJ. IDO1 Signaling Through GCN2 in a Subpopulation of Gr-1+ Cells Shifts the IFNγ/IL6 Balance to Promote Neovascularization. Cancer Immunology Research. PMID 33622713 DOI: 10.1158/2326-6066.CIR-20-0226  1
2020 Merlo LMF, DuHadaway JB, Montgomery JD, Peng WD, Murray PJ, Prendergast GC, Caton AJ, Muller AJ, Mandik-Nayak L. Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses. Frontiers in Immunology. 11: 1861. PMID 32973768 DOI: 10.3389/Fimmu.2020.01861  1
2020 Ladomersky E, Zhai L, Lauing KL, Bell A, Xu J, Kocherginsky M, Zhang B, Wu JD, Podojil JR, Platanias LC, Mochizuki AY, Prins RM, Kumthekar P, Raizer J, Dixit K, ... ... Prendergast GC, et al. Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32546647 DOI: 10.1158/1078-0432.Ccr-19-3874  0.04
2020 Dey S, Mondal A, DuHadaway JB, Sutanto-Ward E, Laury-Kleintop L, Thomas S, Prendergast GC, Mandik-Nayak L, Muller AJ. Abstract 1474: IDO1 signaling supports inflammatory neovascularization Cancer Research. 80: 1474-1474. DOI: 10.1158/1538-7445.Am2020-1474  1
2019 Thomas S, Laury-Kleintop L, Prendergast GC. Reliable detection of indoleamine 2,3 dioxygenase-1 in murine cells and tissues. Methods in Enzymology. 629: 219-233. PMID 31727242 DOI: 10.1016/Bs.Mie.2019.08.008  1
2019 Metz R, Smith C, DuHadaway JB, Chandler P, Baban B, Merlo LMF, Pigott E, Keough MP, Rust S, Mellor AL, Mandik-Nayak L, Muller AJ, Prendergast GC. IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation. International Immunology. 31: 181-182. PMID 31222337 DOI: 10.1093/Intimm/Dxz003  1
2019 Thomas S, Hoxha K, Tran A, Prendergast GC. Bin1 antibody lowers the expression of phosphorylated Tau in Alzheimer's disease. Journal of Cellular Biochemistry. PMID 31211444 DOI: 10.1002/Jcb.29142  1
2019 Manley K, Bravo-Nuevo A, Minton AR, Sedano S, Marcy A, Reichman M, Tobia A, Artlett CM, Gilmour SK, Laury-Kleintop LD, Prendergast GC. Preclinical study of the long-range safety and anti-inflammatory effects of high-dose oral meglumine. Journal of Cellular Biochemistry. PMID 30809852 DOI: 10.1002/Jcb.28492  1
2019 Puligedda RD, Sharma R, Al-Saleem FH, Kouiavskaia D, Velu AB, Kattala CD, Prendergast GC, Lynch DR, Chumakov K, Dessain SK. Capture and display of antibodies secreted by hybridoma cells enables fluorescent on-cell screening. Mabs. 1-13. PMID 30794061 DOI: 10.1080/19420862.2019.1574520  0.01
2019 Lemos H, Huang L, Prendergast GC, Mellor AL. Immune control by amino acid catabolism during tumorigenesis and therapy. Nature Reviews. Cancer. PMID 30696923 DOI: 10.1038/S41568-019-0106-Z  1
2019 Prendergast GC, Nevler A, Muller AJ, Sutanto-Ward E, DuHadaway JB, Nagatomo K, Londin E, O'Hayer K, Cozzitorto JA, Lavu H, Yeo TP, Curtis M, Villatoro T, Leiby BE, Winter JM, et al. Abstract A101: IDO2 host genetic status influences progression and radiotherapy response in pancreatic ductal adenocarcinoma Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A101  1
2018 Almonte-Baldonado R, Bravo-Nuevo A, Gerald D, Benjamin LE, Prendergast GC, Laury-Kleintop LD. RhoB antibody alters retinal vascularization in models of murine retinopathy. Journal of Cellular Biochemistry. PMID 30536763 DOI: 10.1002/Jcb.28213  1
2018 Winters M, DuHadaway JB, Pham KN, Lewis-Ballester A, Badir S, Wai J, Sheikh E, Yeh SR, Prendergast GC, Muller AJ, Malachowski WP. Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase. European Journal of Medicinal Chemistry. 162: 455-464. PMID 30469041 DOI: 10.1016/J.Ejmech.2018.11.010  1
2018 Thomas S, Hoxha K, Alexander W, Gilligan J, Dilbarova R, Whittaker K, Kossenkov A, Prendergast GC, Mullin JM. Intestinal barrier tightening by a cell-penetrating antibody to Bin1, a candidate target for immunotherapy of ulcerative colitis. Journal of Cellular Biochemistry. PMID 30269357 DOI: 10.1002/Jcb.27716  1
2018 Nevler A, Muller AJ, Sutanto-Ward E, DuHadaway JB, Nagatomo K, Londin E, O'Hayer K, Cozzitorto JA, Lavu H, Yeo TP, Curtis MT, Villatoro T, Leiby BE, Mandik-Nayak L, Winter JM, ... ... Prendergast GC, et al. Host gene status influences tumor progression and radiotherapy response in -driven sporadic pancreatic cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30266763 DOI: 10.1158/1078-0432.Ccr-18-0814  1
2018 Fox E, Oliver T, Rowe M, Thomas S, Zakharia Y, Gilman PB, Muller AJ, Prendergast GC. Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer. Frontiers in Oncology. 8: 370. PMID 30254983 DOI: 10.3389/Fonc.2018.00370  1
2018 Muller AJ, Manfredi MG, Zakharia Y, Prendergast GC. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond. Seminars in Immunopathology. PMID 30203227 DOI: 10.1007/S00281-018-0702-0  1
2018 Nevler A, Muller AJ, Cozzitorto JA, Goetz A, Winter JM, Yeo TP, Lavu H, Yeo CJ, Prendergast GC, Brody JR. A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss of Function Polymorphisms and Indoleamine-2,3-Dioxygenase-2. Journal of the American College of Surgeons. PMID 29426021 DOI: 10.1016/J.Jamcollsurg.2017.12.052  1
2018 Prendergast GC, Malachowski WJ, Mondal A, Scherle P, Muller AJ. Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer. International Review of Cell and Molecular Biology. 336: 175-203. PMID 29413890 DOI: 10.1016/Bs.Ircmb.2017.07.004  1
2018 Prendergast GC, Mondal A, Dey S, Laury-Kleintop LD, Muller AJ. Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'. Trends in Cancer. 4: 38-58. PMID 29413421 DOI: 10.1016/J.Trecan.2017.11.005  1
2018 Jiao X, Velasco-Velázquez MA, Wang M, Li Z, Rui H, Peck AR, Korkola JE, Chen X, Xu S, DuHadaway JB, Guerrero-Rodriguez S, Addya S, Sicoli D, Mu Z, Zhang G, ... ... Prendergast GC, et al. CCR5 governs DNA damage and breast cancer stem cell expansion. Cancer Research. PMID 29358169 DOI: 10.1158/0008-5472.Can-17-0915  1
2017 Prendergast GC, Malachowski WP, DuHadaway JB, Muller AJ. Discovery of IDO1 Inhibitors: From Bench to Bedside. Cancer Research. 77: 6795-6811. PMID 29247038 DOI: 10.1158/0008-5472.Can-17-2285  1
2017 Jusof FF, Bakmiwewa SM, Weiser S, Too LK, Metz R, Prendergast GC, Fraser ST, Hunt NH, Ball HJ. Investigation of the Tissue Distribution and Physiological Roles of Indoleamine 2,3-Dioxygenase-2. International Journal of Tryptophan Research : Ijtr. 10: 1178646917735098. PMID 29051706 DOI: 10.1177/1178646917735098  1
2017 Mandik-Nayak L, DuHadaway JB, Mulgrew J, Pigott E, Manley K, Sedano S, Prendergast GC, Laury-Kleintop LD. RhoB blockade selectively inhibits autoantibody production in autoimmune models of rheumatoid arthritis and lupus. Disease Models & Mechanisms. PMID 28882929 DOI: 10.1242/Dmm.029835  1
2017 Thomas S, Izard J, Walsh E, Batich K, Chongsathidkiet P, Clarke G, Sela DA, Muller AJ, Mullin JM, Albert K, Gilligan JP, DiGuilio K, Dilbarova R, Alexander W, Prendergast GC. The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists. Cancer Research. PMID 28292977 DOI: 10.1158/0008-5472.Can-16-2929  1
2017 Merlo LM, Grabler S, DuHadaway JB, Pigott E, Manley K, Prendergast GC, Laury-Kleintop LD, Mandik-Nayak L. Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis. Clinical Immunology (Orlando, Fla.). PMID 28223071 DOI: 10.1016/J.Clim.2017.01.016  1
2017 Mondal A, Sutanto-Ward E, DuHadaway JB, Bravo-Nuevo A, Thomas S, Prendergast GC, Muller AJ. Abstract 2680: A novel pro-tumorigenic role for IDO1 in inflammatory neovascularization Immunology. 77: 2680-2680. DOI: 10.1158/1538-7445.Am2017-2680  1
2016 Caux C, Ramos RN, Prendergast GC, Bendriss-Vermare N, Ménétrier-Caux C. A Milestone Review on How Macrophages Affect Tumor Growth. Cancer Research. 76: 6439-6442. PMID 28148676 DOI: 10.1158/0008-5472.Can-16-2631  0.01
2016 Mondal A, Smith C, DuHadaway JB, Sutanto-Ward E, Prendergast GC, Bravo-Nuevo A, Muller AJ. IDO1 is an Integral Mediator of Inflammatory Neovascularization. Ebiomedicine. PMID 27889479 DOI: 10.1016/J.Ebiom.2016.11.013  1
2016 Kutner T, Kunkel E, Wang Y, George K, Zeger EL, Ali ZA, Prendergast GC, Gilman PB, Wallon UM. Preliminary evaluation of a predictive blood assay to identify patients at high risk of chemotherapy-induced nausea. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. PMID 27734152 DOI: 10.1007/s00520-016-3442-5  1
2016 Merlo LM, DuHadaway JB, Grabler S, Prendergast GC, Muller AJ, Mandik-Nayak L. IDO2 Modulates T Cell-Dependent Autoimmune Responses through a B Cell-Intrinsic Mechanism. Journal of Immunology (Baltimore, Md. : 1950). PMID 27183624 DOI: 10.4049/Jimmunol.1600141  1
2016 Miyagawa T, Ebinuma I, Morohashi Y, Hori Y, Chang MY, Hattori H, Maehara T, Yokoshima S, Fukuyama T, Tsuji S, Iwatsubo T, Prendergast GC, Tomita T. BIN1 regulates BACE1 intracellular trafficking and amyloid-β production. Human Molecular Genetics. PMID 27179792 DOI: 10.1093/Hmg/Ddw146  1
2016 Thomas S, Prendergast GC. Cancer Vaccines: A Brief Overview. Methods in Molecular Biology (Clifton, N.J.). 1403: 755-61. PMID 27076165 DOI: 10.1007/978-1-4939-3387-7_43  1
2016 DuHadaway J, Prendergast GC. Antimetabolite TTL-315 selectively kills glucose-deprived cancer cells and enhances responses to cytotoxic chemotherapy in preclinical models of cancer. Oncotarget. 7: 7372-80. PMID 26840263 DOI: 10.18632/Oncotarget.7058  1
2016 Messerschmidt JL, Prendergast GC, Messerschmidt GL. How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances. The Oncologist. 21: 233-43. PMID 26834161 DOI: 10.1634/theoncologist.2015-0282  0.16
2016 Prendergast GC. Cancer Research: 75th Anniversary of the Field's Most Highly Cited Basic Science Journal. Cancer Research. 76: 3. PMID 26729787 DOI: 10.1158/0008-5472.Can-15-3239  0.01
2016 Kumari A, Iwasaki T, Folk WP, Abdulovic-Cui AL, Pyndiah S, Prendergast GC, Sedivy JM, Sakamuro D. Abstract PR09: c-MYC preserves genomic integrity during DNA replication: a paradigm shift of c-MYC Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Cellcycle16-Pr09  1
2015 Malachowski WP, Winters M, DuHadaway JB, Lewis-Ballester A, Badir S, Wai J, Rahman M, Sheikh E, LaLonde JM, Yeh SR, Prendergast GC, Muller AJ. O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1. European Journal of Medicinal Chemistry. 108: 564-576. PMID 26717206 DOI: 10.1016/J.Ejmech.2015.12.028  1
2015 Bravo-Nuevo A, Brandli AA, Gerhart J, Nichols J, Pitts M, Sutera CK, Assali S, Scheinfeld V, Prendergast GC, Stone J, George-Weinstein M. Neuroprotective Effect of Myo/Nog Cells in the Stressed Retina. Experimental Eye Research. PMID 26688580 DOI: 10.1016/J.Exer.2015.11.023  1
2015 Thomas S, Mercado JM, DuHadaway J, DiGuilio K, Mullin JM, Prendergast GC. Novel Colitis Immunotherapy Targets Bin1 and Improves Colon Cell Barrier Function. Digestive Diseases and Sciences. PMID 26195312 DOI: 10.1007/S10620-015-3804-8  1
2015 Laury-Kleintop LD, Mulgrew JR, Heletz I, Nedelcoviciu RA, Chang MY, Harris DM, Koch WJ, Schneider MD, Muller AJ, Prendergast GC. Cardiac-Specific Disruption of Bin1 in Mice Enables a Model of Stress- and Age-Associated Dilated Cardiomyopathy. Journal of Cellular Biochemistry. PMID 25939245 DOI: 10.1002/Jcb.25198  1
2015 Prendergast GC. A perspective on cancer as an abortive autoimmune response to altered-self. Cancer Research. 75: 3-4. PMID 25559989 DOI: 10.1158/0008-5472.Can-14-3532  0.01
2015 Wallon UM, Sabol JL, Zemba-Palko V, DuHadaway JS, Sutanto-Ward E, Ali ZA, Gilman PB, Ciocca RM, Carp NZ, Prendergast GC. Abstract P6-08-54: TIMP-4 is a prognostic and predictive marker in triple-negative breast cancers Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P6-08-54  1
2015 Mondal A, DuHadaway JB, Sutanto-Ward E, Smith C, Prendergast GC, Bravo-Nuevo A, Muller AJ. Abstract 5223: A novel pro-angiogenic role for IDO1 in inflammatory tumor promotion Cancer Research. 75: 5223-5223. DOI: 10.1158/1538-7445.Am2015-5223  1
2014 Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, ... ... Prendergast GC, et al. Classification of current anticancer immunotherapies. Oncotarget. 5: 12472-508. PMID 25537519 DOI: 10.18632/Oncotarget.2998  0.01
2014 Prendergast GC, Metz R, Muller AJ, Merlo LM, Mandik-Nayak L. IDO2 in Immunomodulation and Autoimmune Disease. Frontiers in Immunology. 5: 585. PMID 25477879 DOI: 10.3389/Fimmu.2014.00585  1
2014 Bessede A, Gargaro M, Pallotta MT, Matino D, Servillo G, Brunacci C, Bicciato S, Mazza EM, Macchiarulo A, Vacca C, Iannitti R, Tissi L, Volpi C, Belladonna ML, Orabona C, ... ... Prendergast GC, et al. Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature. 511: 184-90. PMID 24930766 DOI: 10.1038/Nature13323  1
2014 Pigott E, DuHadaway JB, Muller AJ, Gilmour S, Prendergast GC, Mandik-Nayak L. 1-Methyl-tryptophan synergizes with methotrexate to alleviate arthritis in a mouse model of arthritis. Autoimmunity. 47: 409-18. PMID 24798341 DOI: 10.3109/08916934.2014.914507  1
2014 Prendergast GC, Smith C, Thomas S, Mandik-Nayak L, Laury-Kleintop L, Metz R, Muller AJ. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunology, Immunotherapy : Cii. 63: 721-35. PMID 24711084 DOI: 10.1007/S00262-014-1549-4  1
2014 Bravo-Nuevo A, Marcy A, Huang M, Kappler F, Mulgrew J, Laury-Kleintop L, Reichman M, Tobia A, Prendergast GC. Meglumine exerts protective effects against features of metabolic syndrome and type II diabetes. Plos One. 9: e90031. PMID 24587200 DOI: 10.1371/Journal.Pone.0090031  1
2014 Merlo LM, Pigott E, DuHadaway JB, Grabler S, Metz R, Prendergast GC, Mandik-Nayak L. IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis. Journal of Immunology (Baltimore, Md. : 1950). 192: 2082-90. PMID 24489090 DOI: 10.4049/Jimmunol.1303012  1
2014 Metz R, Smith C, DuHadaway JB, Chandler P, Baban B, Merlo LM, Pigott E, Keough MP, Rust S, Mellor AL, Mandik-Nayak L, Muller AJ, Prendergast GC. IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation. International Immunology. 26: 357-67. PMID 24402311 DOI: 10.1093/Intimm/Dxt073  1
2014 Trabanelli S, Očadlíková D, Ciciarello M, Salvestrini V, Lecciso M, Jandus C, Metz R, Evangelisti C, Laury-Kleintop L, Romero P, Prendergast GC, Curti A, Lemoli RM. The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells. Journal of Immunology (Baltimore, Md. : 1950). 192: 1231-40. PMID 24391212 DOI: 10.4049/Jimmunol.1300720  1
2014 Thomas S, DuHadaway J, Prendergast GC, Laury-Kleintop L. Specific in situ detection of murine indoleamine 2, 3-dioxygenase. Journal of Cellular Biochemistry. 115: 391-6. PMID 24123235 DOI: 10.1002/Jcb.24674  1
2014 Muller AJ, Smith C, Chang MY, DuHadaway J, Mondal A, Flick H, Parker K, Beury D, Ostrand-Rosenberg S, Prendergast GC. Abstract 3665: IDO1 is an integrative determinant of tumor-promoting, pathogenic inflammation Cancer Research. 74: 3665-3665. DOI: 10.1158/1538-7445.Am2014-3665  1
2014 Prendergast GC, Smith C, Thomas S, Mandik-Nayak L, Laury-Kleintop L, Metz R, Muller AJ. IDO in inflammatory programming and immune suppression in cancer Tumor-Induced Immune Suppression: Mechanisms and Therapeutic Reversal. 311-346. DOI: 10.1007/978-1-4899-8056-4_11  1
2013 Gerald D, Adini I, Shechter S, Perruzzi C, Varnau J, Hopkins B, Kazerounian S, Kurschat P, Blachon S, Khedkar S, Bagchi M, Sherris D, Prendergast GC, Klagsbrun M, Stuhlmann H, et al. RhoB controls coordination of adult angiogenesis and lymphangiogenesis following injury by regulating VEZF1-mediated transcription. Nature Communications. 4: 2824. PMID 24280686 DOI: 10.1038/Ncomms3824  1
2013 Eldredge HB, Denittis A, Duhadaway JB, Chernick M, Metz R, Prendergast GC. CONCURRENT WHOLE BRAIN RADIOTHERAPY AND SHORT-COURSE CHLOROQUINE IN PATIENTS WITH BRAIN METASTASES: A PILOT TRIAL. Journal of Radiation Oncology. 2. PMID 24187608 DOI: 10.1007/S13566-013-0111-X  1
2013 Sawyers CL, Abate-Shen C, Anderson KC, Barker A, Baselga J, Berger NA, Foti M, Jemal A, Lawrence TS, Li CI, Mardis ER, Neumann PJ, Pardoll DM, Prendergast GC, et al. AACR Cancer Progress Report 2013. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: S4-98. PMID 24045178 DOI: 10.1158/1078-0432.Ccr-13-2107  1
2013 Simionescu-Bankston A, Leoni G, Wang Y, Pham PP, Ramalingam A, DuHadaway JB, Faundez V, Nusrat A, Prendergast GC, Pavlath GK. The N-BAR domain protein, Bin3, regulates Rac1- and Cdc42-dependent processes in myogenesis. Developmental Biology. 382: 160-71. PMID 23872330 DOI: 10.1016/J.Ydbio.2013.07.004  1
2013 Kazerounian S, Gerald D, Huang M, Chin YR, Udayakumar D, Zheng N, O'Donnell RK, Perruzzi C, Mangiante L, Pourat J, Phung TL, Bravo-Nuevo A, Shechter S, McNamara S, Duhadaway JB, ... ... Prendergast GC, et al. RhoB differentially controls Akt function in tumor cells and stromal endothelial cells during breast tumorigenesis. Cancer Research. 73: 50-61. PMID 23135917 DOI: 10.1158/0008-5472.Can-11-3055  1
2013 Li J, Ward KM, Zhang D, Dayanandam E, Denittis AS, Prendergast GC, Ayene IS. A bioactive probe of the oxidative pentose phosphate cycle: novel strategy to reverse radioresistance in glucose deprived human colon cancer cells. Toxicology in Vitro : An International Journal Published in Association With Bibra. 27: 367-77. PMID 22926048 DOI: 10.1016/J.Tiv.2012.08.012  0.01
2013 Smith C, Prendergast GC. Inflammatory programming and immune modulation in cancer by IDO Atlas of Genetics and Cytogenetics in Oncology and Haematology. DOI: 10.4267/2042/51878  1
2013 Kunkel EK, DuHadaway J, Sutanto-Ward E, Birnhak LN, Ringqvist JR, Ali ZA, Gilman PB, Prendergast GC, Wallon UM. Abstract B070: TIMP-4 – prognostic marker and treatment target for triple-negative breast cancers Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-B070  1
2012 Metz R, Rust S, Duhadaway JB, Mautino MR, Munn DH, Vahanian NN, Link CJ, Prendergast GC. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology. 1: 1460-1468. PMID 23264892 DOI: 10.4161/Onci.21716  1
2012 Takahashi N, Duprez L, Grootjans S, Cauwels A, Nerinckx W, Duhadaway JB, Goossens V, Roelandt R, Van Hauwermeiren F, Libert C, Declercq W, Callewaert N, Prendergast GC, Degterev A, Yuan J, et al. Necrostatin-1 analogues: Critical issues on the specificity, activity and in vivo use in experimental disease models Cell Death and Disease. 3. PMID 23190609 DOI: 10.1038/Cddis.2012.176  1
2012 Janson C, Kasahara N, Prendergast GC, Colicelli J. RIN3 is a negative regulator of mast cell responses to SCF. Plos One. 7: e49615. PMID 23185384 DOI: 10.1371/Journal.Pone.0049615  1
2012 Prendergast GC, Metz R. A perspective on new immune adjuvant principles: Reprogramming inflammatory states to permit clearance of cancer cells and other age-associated cellular pathologies. Oncoimmunology. 1: 924-929. PMID 23162760 DOI: 10.4161/Onci.21358  1
2012 Prendergast GC. Immunological thought in the mainstream of cancer research: Past divorce, recent remarriage and elective affinities of the future. Oncoimmunology. 1: 793-797. PMID 23162746 DOI: 10.4161/Onci.20909  0.01
2012 McGaha TL, Huang L, Lemos H, Metz R, Mautino M, Prendergast GC, Mellor AL. Amino acid catabolism: a pivotal regulator of innate and adaptive immunity. Immunological Reviews. 249: 135-57. PMID 22889220 DOI: 10.1111/J.1600-065X.2012.01149.X  1
2012 Smith C, Chang MY, Parker KH, Beury DW, DuHadaway JB, Flick HE, Boulden J, Sutanto-Ward E, Soler AP, Laury-Kleintop LD, Mandik-Nayak L, Metz R, Ostrand-Rosenberg S, Prendergast GC, Muller AJ. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discovery. 2: 722-35. PMID 22822050 DOI: 10.1158/2159-8290.Cd-12-0014  1
2012 Wojciak-Stothard B, Zhao L, Oliver E, Dubois O, Wu Y, Kardassis D, Vasilaki E, Huang M, Mitchell JA, Harrington LS, Louise H, Prendergast GC, Wilkins MR. Role of RhoB in the regulation of pulmonary endothelial and smooth muscle cell responses to hypoxia. Circulation Research. 110: 1423-34. PMID 22539766 DOI: 10.1161/CIRCRESAHA.112.264473  1
2012 Chang MY, Boulden J, Valenzano MC, Soler AP, Muller AJ, Mullin JM, Prendergast GC. Bin1 attenuation suppresses experimental colitis by enforcing intestinal barrier function. Digestive Diseases and Sciences. 57: 1813-21. PMID 22526583 DOI: 10.1007/S10620-012-2147-Y  1
2012 Li J, Zhang D, Ward KM, Prendergast GC, Ayene IS. Hydroxyethyl disulfide as an efficient metabolic assay for cell viability in vitro. Toxicology in Vitro : An International Journal Published in Association With Bibra. 26: 603-12. PMID 22321380 DOI: 10.1016/J.Tiv.2012.01.007  0.04
2012 Divanovic S, Sawtell NM, Trompette A, Warning JI, Dias A, Cooper AM, Yap GS, Arditi M, Shimada K, Duhadaway JB, Prendergast GC, Basaraba RJ, Mellor AL, Munn DH, Aliberti J, et al. Opposing biological functions of tryptophan catabolizing enzymes during intracellular infection. The Journal of Infectious Diseases. 205: 152-61. PMID 21990421 DOI: 10.1093/Infdis/Jir621  1
2012 Smith C, Chang M, Flick H, DuHadaway J, Mandik-Nayak L, Laury-Kleintop L, Parker K, Beury D, Ostrand-Rosenberg S, Prendergast GC, Muller AJ. Abstract 295: IDO drives tumor-promoting, pathogenic inflammation in lung Cancer Research. 72: 295-295. DOI: 10.1158/1538-7445.Am2012-295  1
2012 Divanovic S, Sawtell NM, Trompette A, Warning JI, Dias A, Cooper AM, Yap GS, Arditi M, Shimada K, Duhadaway JB, Prendergast GC, Basaraba RJ, Mellor AL, Munn DH, Aliberti J, et al. Reply to Schroecksnadel, et al Journal of Infectious Diseases. 205: 1618. DOI: 10.1093/Infdis/Jis247  1
2012 Prendergast GC, Metz R, Chang MY, Smith C, Muller AJ, Ostrand-Rosenberg S. Indoleamine 2,3-dioxygenase amino acid metabolism and tumour-associated macrophages: regulation in cancer-associated inflammation and immune escape Tumour-Associated Macrophages. 2147483647: 91-104. DOI: 10.1007/978-1-4614-0662-4_7  1
2011 Chang MY, Smith C, DuHadaway JB, Pyle JR, Boulden J, Soler AP, Muller AJ, Laury-Kleintop LD, Prendergast GC. Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase. Cancer Biology & Therapy. 12: 1050-8. PMID 22157149 DOI: 10.4161/cbt.12.12.18142  1
2011 Barberan S, McNair K, Iqbal K, Smith NC, Prendergast GC, Stone TW, Cobb SR, Morris BJ. Altered apoptotic responses in neurons lacking RhoB GTPase. The European Journal of Neuroscience. 34: 1737-46. PMID 22098422 DOI: 10.1111/J.1460-9568.2011.07891.X  1
2011 Ha NH, Nair VS, Reddy DN, Mudvari P, Ohshiro K, Ghanta KS, Pakala SB, Li DQ, Costa L, Lipton A, Badwe RA, Fuqua S, Wallon M, Prendergast GC, Kumar R. Lactoferrin-endothelin-1 axis contributes to the development and invasiveness of triple-negative breast cancer phenotypes. Cancer Research. 71: 7259-69. PMID 22006997 DOI: 10.1158/0008-5472.Can-11-1143  1
2011 Prendergast GC. Cancer: Why tumours eat tryptophan. Nature. 478: 192-4. PMID 21993754 DOI: 10.1038/478192A  0.01
2011 Zhang C, Elkahloun AG, Liao H, Delaney S, Saber B, Morrow B, Prendergast GC, Hollander MC, Gills JJ, Dennis PA. Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells. Molecular Cancer Therapeutics. 10: 1137-48. PMID 21551261 DOI: 10.1158/1535-7163.Mct-10-1028  1
2011 Prendergast GC, Chang MY, Mandik-Nayak L, Metz R, Muller AJ. Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases. Current Medicinal Chemistry. 18: 2257-62. PMID 21517753 DOI: 10.2174/092986711795656072  1
2011 Prendergast GC. Perspectives on emerging trends in cancer research. Cancer Research. 71: 2027-8. PMID 21406392 DOI: 10.1158/0008-5472.Can-11-0427  0.01
2011 Huang M, Satchell L, Duhadaway JB, Prendergast GC, Laury-Kleintop LD. RhoB links PDGF signaling to cell migration by coordinating activation and localization of Cdc42 and Rac. Journal of Cellular Biochemistry. 112: 1572-84. PMID 21344485 DOI: 10.1002/Jcb.23069  1
2011 Bravo-Nuevo A, Sugimoto H, Iyer S, Fallon Z, Lucas JM, Kazerounian S, Prendergast GC, Kalluri R, Shapiro NI, Benjamin LE. RhoB loss prevents streptozotocin-induced diabetes and ameliorates diabetic complications in mice. The American Journal of Pathology. 178: 245-52. PMID 21224061 DOI: 10.1016/J.Ajpath.2010.11.040  1
2011 Chang MY, Metz R, Muller AJ, Prendergast GC. IDO2 (indoleamine 2,3-dioxygenase 2) Atlas of Genetics and Cytogenetics in Oncology and Haematology. DOI: 10.4267/2042/44688  1
2011 Wallon U, Sabol J, Zemba-Palko V, Carp N, Ciocca R, Wojciechowski B, Prendergast G. P4-09-21: A Novel Prognostic Marker for Triple-Negative Breast Cancers. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P4-09-21  1
2010 Tian L, Huang K, DuHadaway JB, Prendergast GC, Stambolian D. Genomic profiling of miRNAs in two human lens cell lines. Current Eye Research. 35: 812-8. PMID 20795863 DOI: 10.3109/02713683.2010.489182  1
2010 Muller AJ, DuHadaway JB, Chang MY, Ramalingam A, Sutanto-Ward E, Boulden J, Soler AP, Mandik-Nayak L, Gilmour SK, Prendergast GC. Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion. Cancer Immunology, Immunotherapy : Cii. 59: 1655-63. PMID 20640572 DOI: 10.1007/S00262-010-0891-4  1
2010 Muller AJ, Mandik-Nayak L, Prendergast GC. Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation. Immunotherapy. 2: 293-7. PMID 20635895 DOI: 10.2217/Imt.10.22  1
2010 Donover PS, Wojciechowski BS, Thirumaran R, Zemba-Palko V, Prendergast GC, Wallon UM. Development of a monoclonal antibody that specifically detects tissue inhibitor of metalloproteinase-4 (TIMP-4) in formalin-fixed, paraffin-embedded human tissues. Journal of Cellular Biochemistry. 110: 1255-61. PMID 20564221 DOI: 10.1002/Jcb.22641  1
2010 Metz R, Duhadaway JB, Rust S, Munn DH, Muller AJ, Mautino M, Prendergast GC. Zinc protoporphyrin IX stimulates tumor immunity by disrupting the immunosuppressive enzyme indoleamine 2,3-dioxygenase. Molecular Cancer Therapeutics. 9: 1864-71. PMID 20530717 DOI: 10.1158/1535-7163.Mct-10-0185  1
2010 Prendergast GC, Metz R, Muller AJ. Towards a genetic definition of cancer-associated inflammation: role of the IDO pathway. The American Journal of Pathology. 176: 2082-7. PMID 20228228 DOI: 10.2353/Ajpath.2010.091173  1
2010 McNair K, Spike R, Guilding C, Prendergast GC, Stone TW, Cobb SR, Morris BJ. A role for RhoB in synaptic plasticity and the regulation of neuronal morphology. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 30: 3508-17. PMID 20203211 DOI: 10.1523/Jneurosci.5386-09.2010  1
2010 Ciorba MA, Bettonville EE, McDonald KG, Metz R, Prendergast GC, Newberry RD, Stenson WF. Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis. Journal of Immunology (Baltimore, Md. : 1950). 184: 3907-16. PMID 20181893 DOI: 10.4049/Jimmunol.0900291  1
2010 Muller AJ, DuHadaway JB, Jaller D, Curtis P, Metz R, Prendergast GC. Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate. Cancer Research. 70: 1845-53. PMID 20160032 DOI: 10.1158/0008-5472.Can-09-3613  1
2010 Prendergast GC. In their own words: interviews with Cell Cycle. Cell Cycle (Georgetown, Tex.). 9: 233-4. PMID 20081353 DOI: 10.4161/Cc.9.2.11150  0.01
2010 Ward KM, Li J, Zhang D, Dayanandam E, DeNittis AS, Prendergast GC, Ayene IS. Abstract 1392: HEDS selectively radiosensitizes human cancer cells in glucose-deprived environments via inhibition of Ku protein function Cancer Research. 70: 1392-1392. DOI: 10.1158/1538-7445.Am10-1392  0.04
2010 Muller AJ, DuHadaway JB, Chang MY, Soler AP, Prendergast GC. Abstract 1347: Immune escape mediator IDO is a crucial defining element of ‘cancer-associated’ inflammation in the tumor microenvironment Cancer Research. 70: 1347-1347. DOI: 10.1158/1538-7445.Am10-1347  1
2009 DeWard AD, Leali K, West RA, Prendergast GC, Alberts AS. Loss of RhoB expression enhances the myelodysplastic phenotype of mammalian diaphanous-related Formin mDia1 knockout mice. Plos One. 4: e7102. PMID 19768111 DOI: 10.1371/Journal.Pone.0007102  1
2009 Liss M, Sreedhar N, Keshgegian A, Sauter G, Chernick MR, Prendergast GC, Wallon UM. Tissue inhibitor of metalloproteinase-4 is elevated in early-stage breast cancers with accelerated progression and poor clinical course. The American Journal of Pathology. 175: 940-6. PMID 19700750 DOI: 10.2353/Ajpath.2009.081094  1
2009 Scott GN, DuHadaway J, Pigott E, Ridge N, Prendergast GC, Muller AJ, Mandik-Nayak L. The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. Journal of Immunology (Baltimore, Md. : 1950). 182: 7509-17. PMID 19494274 DOI: 10.4049/Jimmunol.0804328  1
2009 Witkiewicz AK, Costantino CL, Metz R, Muller AJ, Prendergast GC, Yeo CJ, Brody JR. Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. Journal of the American College of Surgeons. 208: 781-7; discussion 78. PMID 19476837 DOI: 10.1016/J.Jamcollsurg.2008.12.018  1
2009 Prendergast GC, Metz R, Muller AJ. IDO recruits Tregs in melanoma. Cell Cycle (Georgetown, Tex.). 8: 1818-9. PMID 19471123 DOI: 10.4161/Cc.8.12.8887  1
2009 Prendergast GC, Muller AJ, Ramalingam A, Chang MY. BAR the door: cancer suppression by amphiphysin-like genes. Biochimica Et Biophysica Acta. 1795: 25-36. PMID 18930786 DOI: 10.1016/J.Bbcan.2008.09.001  1
2009 Dalenc F, Filleron T, Keller L, Meunier, Malissein, Bergé Y, Roché H, Favre G, Prendergast G, Lacroix-Triki M, Doisneau-sixou S. Correlation between RhoB and Estrogen Receptor α (ERα) Expressions: From Experimental Data to Human Breast Tumors. Cancer Research. 69: 5146-5146. DOI: 10.1158/0008-5472.Sabcs-09-5146  0.01
2009 Katz JB, Muller AJ, Metz R, Prendergast GC. Immune escape: Role of indoleamine 2,3-dioxygenase in tumor tolerance Targeted Cancer Immune Therapy. 257-283. DOI: 10.1007/978-1-4419-0170-5_15  1
2008 Muller AJ, Sharma MD, Chandler PR, Duhadaway JB, Everhart ME, Johnson BA, Kahler DJ, Pihkala J, Soler AP, Munn DH, Prendergast GC, Mellor AL. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proceedings of the National Academy of Sciences of the United States of America. 105: 17073-8. PMID 18952840 DOI: 10.1073/Pnas.0806173105  1
2008 Chien J, Narita K, Rattan R, Giri S, Shridhar R, Staub J, Beleford D, Lai J, Roberts LR, Molina J, Kaufmann SH, Prendergast GC, Shridhar V. A role for candidate tumor-suppressor gene TCEAL7 in the regulation of c-Myc activity, cyclin D1 levels and cellular transformation Oncogene. 27: 7223-7234. PMID 18806825 DOI: 10.1038/Onc.2008.360  1
2008 Kumar S, Jaller D, Patel B, LaLonde JM, DuHadaway JB, Malachowski WP, Prendergast GC, Muller AJ. Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase Journal of Medicinal Chemistry. 51: 4968-4977. PMID 18665584 DOI: 10.1021/Jm800512Z  1
2008 Katz JB, Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunological Reviews. 222: 206-21. PMID 18364004 DOI: 10.1111/J.1600-065X.2008.00610.X  1
2008 Ramalingam A, Duhadaway JB, Sutanto-Ward E, Wang Y, Dinchuk J, Huang M, Donover PS, Boulden J, McNally LM, Soler AP, Muller AJ, Duncan MK, Prendergast GC. Bin3 deletion causes cataracts and increased susceptibility to lymphoma during aging. Cancer Research. 68: 1683-90. PMID 18339847 DOI: 10.1158/0008-5472.Can-07-6072  1
2008 Kumar S, Malachowski WP, DuHadaway JB, LaLonde JM, Carroll PJ, Jaller D, Metz R, Prendergast GC, Muller AJ. Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. Journal of Medicinal Chemistry. 51: 1706-18. PMID 18318466 DOI: 10.1021/Jm7014155  1
2008 McDonnell TJ, Chari NS, Cho-Vega JH, Troncoso P, Wang X, Bueso-Ramos CE, Coombes K, Brisbay S, Lopez R, Prendergast G, Logothetis C, Do KA. Biomarker expression patterns that correlate with high grade features in treatment naive, organ-confined prostate cancer. Bmc Medical Genomics. 1: 1. PMID 18237448 DOI: 10.1186/1755-8794-1-1  1
2008 Li Z, Wang C, Jiao X, Katiyar S, Casimiro MC, Prendergast GC, Powell MJ, Pestell RG. Alternate cyclin D1 mRNA splicing modulates p27KIP1 binding and cell migration. The Journal of Biological Chemistry. 283: 7007-15. PMID 18180298 DOI: 10.1074/Jbc.M706992200  1
2008 Banerjee T, Duhadaway JB, Gaspari P, Sutanto-Ward E, Munn DH, Mellor AL, Malachowski WP, Prendergast GC, Muller AJ. A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene. 27: 2851-7. PMID 18026137 DOI: 10.1038/Sj.Onc.1210939  1
2007 Huang M, Duhadaway JB, Prendergast GC, Laury-Kleintop LD. RhoB regulates PDGFR-beta trafficking and signaling in vascular smooth muscle cells. Arteriosclerosis, Thrombosis, and Vascular Biology. 27: 2597-605. PMID 17951322 DOI: 10.1161/Atvbaha.107.154211  1
2007 Kamasani U, Duhadaway JB, Alberts AS, Prendergast GC. mDia function is critical for the cell suicide program triggered by farnesyl transferase inhibition. Cancer Biology & Therapy. 6: 1422-7. PMID 17786040 DOI: 10.4161/Cbt.6.9.4546  1
2007 Chang MY, Boulden J, Katz JB, Wang L, Meyer TJ, Soler AP, Muller AJ, Prendergast GC. Bin1 ablation increases susceptibility to cancer during aging, particularly lung cancer. Cancer Research. 67: 7605-12. PMID 17699764 DOI: 10.1158/0008-5472.Can-07-1100  1
2007 Ramalingam A, Farmer GE, Stamato TD, Prendergast GC. Bin1 interacts with and restrains the DNA end-binding protein complex Ku. Cell Cycle (Georgetown, Tex.). 6: 1914-8. PMID 17671430 DOI: 10.4161/Cc.6.15.4514  1
2007 Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Research. 67: 7082-7. PMID 17671174 DOI: 10.1158/0008-5472.Can-07-1872  1
2007 Ramalingam A, Prendergast GC. Bin1 homolog hob1 supports a Rad6-Set1 pathway of transcriptional repression in fission yeast. Cell Cycle (Georgetown, Tex.). 6: 1655-62. PMID 17611416 DOI: 10.4161/Cc.6.13.4413  1
2007 Prendergast GC, Jaffee EM. Cancer immunologists and cancer biologists: why we didn't talk then but need to now. Cancer Research. 67: 3500-4. PMID 17413003 DOI: 10.1158/0008-5472.Can-06-4626  0.01
2007 Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in immune suppression and cancer. Current Cancer Drug Targets. 7: 31-40. PMID 17305476 DOI: 10.2174/156800907780006896  1
2007 Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, Mellor AL, Prendergast GC, Munn DH. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Research. 67: 792-801. PMID 17234791 DOI: 10.1158/0008-5472.Can-06-2925  1
2007 Ghaneie A, Zemba-Palko V, Itoh H, Itoh K, Sakamuro D, Nakamura S, Soler AP, Prendergast GC. Bin1 attenuation in breast cancer is correlated to nodal metastasis and reduced survival. Cancer Biology & Therapy. 6: 192-4. PMID 17218774 DOI: 10.4161/Cbt.6.2.3587  1
2007 Chang MY, Boulden J, Sutanto-Ward E, Duhadaway JB, Soler AP, Muller AJ, Prendergast GC. Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression. Cancer Research. 67: 100-7. PMID 17210688 DOI: 10.1158/0008-5472.Can-06-2742  1
2007 Muller AJ, Metz R, Prendergast GC. Differential targeting of tryptophan catabolism in tumors and in tumor-draining lymph nodes by stereoisomers of the IDO inhibitor 1-methyl-tryptophan International Congress Series. 1304: 250-261. DOI: 10.1016/j.ics.2007.07.042  1
2007 Muller AJ, Prendergast GC. Indoleamine 2,3-Dioxygenase in Immune Escape: Regulation and Therapeutic Inhibition Cancer Immunotherapy. 347-368. DOI: 10.1016/B978-012372551-6/50083-3  1
2006 Li Z, Wang C, Prendergast GC, Pestell RG. Cyclin D1 functions in cell migration. Cell Cycle (Georgetown, Tex.). 5: 2440-2. PMID 17106256 DOI: 10.4161/Cc.5.21.3428  1
2006 Casal E, Federici L, Zhang W, Fernandez-Recio J, Priego EM, Miguel RN, DuHadaway JB, Prendergast GC, Luisi BF, Laue ED. The crystal structure of the BAR domain from human Bin1/amphiphysin II and its implications for molecular recognition. Biochemistry. 45: 12917-28. PMID 17059209 DOI: 10.1021/Bi060717K  1
2006 Gaspari P, Banerjee T, Malachowski WP, Muller AJ, Prendergast GC, DuHadaway J, Bennett S, Donovan AM. Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. Journal of Medicinal Chemistry. 49: 684-92. PMID 16420054 DOI: 10.1021/Jm0508888  1
2005 Prendergast GC. Chasing cancer: from genes to drugs. Cancer Biology & Therapy. 4: 901-5. PMID 16177560 DOI: 10.4161/Cbt.4.8.2154  0.01
2005 Muller AJ, Prendergast GC. Marrying immunotherapy with chemotherapy: why say IDO? Cancer Research. 65: 8065-8. PMID 16166276 DOI: 10.1158/0008-5472.Can-05-2213  1
2005 Masumi A, Aizaki H, Suzuki T, DuHadaway JB, Prendergast GC, Komuro K, Fukazawa H. Reduction of hepatitis C virus NS5A phosphorylation through its interaction with amphiphysin II. Biochemical and Biophysical Research Communications. 336: 572-8. PMID 16139795 DOI: 10.1016/J.Bbrc.2005.08.142  1
2005 Muller AJ, Malachowski WP, Prendergast GC. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opinion On Therapeutic Targets. 9: 831-49. PMID 16083346 DOI: 10.1517/14728222.9.4.831  1
2005 Kamasani U, Prendergast GC. Genetic response to DNA damage: proapoptotic targets of RhoB include modules for p53 response and susceptibility to Alzheimer's disease. Cancer Biology & Therapy. 4: 282-8. PMID 15876868 DOI: 10.4161/Cbt.4.3.1498  1
2005 Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nature Medicine. 11: 312-9. PMID 15711557 DOI: 10.1038/Nm1196  1
2005 Pedrini S, Carter TL, Prendergast G, Petanceska S, Ehrlich ME, Gandy S. Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. Plos Medicine. 2: e18. PMID 15647781 DOI: 10.1371/Journal.Pmed.0020018  1
2004 Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Targeted deletion of the suppressor gene bin1/amphiphysin2 accentuates the neoplastic character of transformed mouse fibroblasts. Cancer Biology & Therapy. 3: 1236-42. PMID 15611650 DOI: 10.4161/Cbt.3.12.1232  1
2004 Sandilands E, Cans C, Fincham VJ, Brunton VG, Mellor H, Prendergast GC, Norman JC, Superti-Furga G, Frame MC. RhoB and actin polymerization coordinate Src activation with endosome-mediated delivery to the membrane. Developmental Cell. 7: 855-69. PMID 15572128 DOI: 10.1016/J.Devcel.2004.09.019  1
2004 Kamasani U, Huang M, Duhadaway JB, Prochownik EV, Donover PS, Prendergast GC. Cyclin B1 is a critical target of RhoB in the cell suicide program triggered by farnesyl transferase inhibition. Cancer Research. 64: 8389-96. PMID 15548709 DOI: 10.1158/0008-5472.Can-04-2437  1
2003 Adini I, Rabinovitz I, Sun JF, Prendergast GC, Benjamin LE. RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development. Genes & Development. 17: 2721-32. PMID 14597666 DOI: 10.1101/Gad.1134603  1
2003 Prendergast GC. Signal transduction: putting translation before transcription. Cancer Cell. 4: 244-5. PMID 14585349 DOI: 10.1016/S1535-6108(03)00247-2  0.01
2003 Tajiri T, Liu X, Thompson PM, Tanaka S, Suita S, Zhao H, Maris JM, Prendergast GC, Hogarty MD. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 3345-55. PMID 12960121  0.04
2003 Kamasani U, Liu AX, Prendergast GC. Genetic response to farnesyltransferase inhibitors: proapoptotic targets of RhoB. Cancer Biology & Therapy. 2: 273-80. PMID 12878865 DOI: 10.4161/Cbt.2.3.385  1
2003 DuHadaway JB, Du W, Donover S, Baker J, Liu AX, Sharp DM, Muller AJ, Prendergast GC. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1. Oncogene. 22: 3578-88. PMID 12789266 DOI: 10.1038/Sj.Onc.1206481  1
2003 Muller AJ, Baker JF, DuHadaway JB, Ge K, Farmer G, Donover PS, Meade R, Reid C, Grzanna R, Roach AH, Shah N, Soler AP, Prendergast GC. Targeted disruption of the murine Bin1/Amphiphysin II gene does not disable endocytosis but results in embryonic cardiomyopathy with aberrant myofibril formation. Molecular and Cellular Biology. 23: 4295-306. PMID 12773571 DOI: 10.1128/Mcb.23.12.4295-4306.2003  1
2003 Zeng PY, Rane N, Du W, Chintapalli J, Prendergast GC. Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors. Oncogene. 22: 1124-34. PMID 12606940 DOI: 10.1038/Sj.Onc.1206181  1
2003 Routhier EL, Donover PS, Prendergast GC. hob1+, the fission yeast homolog of Bin1, is dispensable for endocytosis or actin organization, but required for the response to starvation or genotoxic stress. Oncogene. 22: 637-48. PMID 12569356 DOI: 10.1038/sj.onc.1206162  1
2003 DuHadaway JB, Lynch FJ, Brisbay S, Bueso-Ramos C, Troncoso P, McDonnell T, Prendergast GC. Immunohistochemical analysis of Bin1/Amphiphysin II in human tissues: diverse sites of nuclear expression and losses in prostate cancer. Journal of Cellular Biochemistry. 88: 635-42. PMID 12532338 DOI: 10.1002/Jcb.10380  1
2002 Prendergast GC. Farnesyltransferase inhibitors: potential therapeutic for inflammatory breast cancer? Breast Disease. 15: 25-32. PMID 15687643 DOI: 10.3233/Bd-2002-15104  0.01
2002 van Golen KL, Bao L, DiVito MM, Wu Z, Prendergast GC, Merajver SD. Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. Molecular Cancer Therapeutics. 1: 575-83. PMID 12479217  1
2002 Prendergast GC. CHK and MEK inhibitors team up to trigger cancer cell suicide. Cancer Biology & Therapy. 1: 254-5. PMID 12432272 DOI: 10.4161/Cbt.76  0.01
2002 Zhang B, Prendergast GC, Fenton RG. Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression. Cancer Research. 62: 450-8. PMID 11809695  0.01
2001 Liu AX, Rane N, Liu JP, Prendergast GC. RhoB is dispensable for mouse development, but it modifies susceptibility to tumor formation as well as cell adhesion and growth factor signaling in transformed cells. Molecular and Cellular Biology. 21: 6906-12. PMID 11564874 DOI: 10.1128/Mcb.21.20.6906-6912.2001  1
2001 Liu Ax, Cerniglia GJ, Bernhard EJ, Prendergast GC. RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage. Proceedings of the National Academy of Sciences of the United States of America. 98: 6192-7. PMID 11353846 DOI: 10.1073/Pnas.111137198  0.01
2001 DuHadaway JB, Sakamuro D, Ewert DL, Prendergast GC. Bin1 mediates apoptosis by c-Myc in transformed primary cells. Cancer Research. 61: 3151-6. PMID 11306501  1
2001 Routhier EL, Burn TC, Abbaszade I, Summers M, Albright CF, Prendergast GC. Human BIN3 complements the F-actin localization defects caused by loss of Hob3p, the fission yeast homolog of Rvs161p. The Journal of Biological Chemistry. 276: 21670-7. PMID 11274158 DOI: 10.1074/Jbc.M101096200  1
2000 Elliott K, Ge K, Du W, Prendergast GC. The c-Myc-interacting adaptor protein Bin1 activates a caspase-independent cell death program. Oncogene. 19: 4669-84. PMID 11032017 DOI: 10.1038/Sj.Onc.1203681  1
2000 Liu A, Prendergast GC. Geranylgeranylated RhoB is sufficient to mediate tissue-specific suppression of Akt kinase activity by farnesyltransferase inhibitors. Febs Letters. 481: 205-8. PMID 11007964 DOI: 10.1016/S0014-5793(00)02003-2  0.4
2000 Liu Ax, Du W, Liu JP, Jessell TM, Prendergast GC. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors. Molecular and Cellular Biology. 20: 6105-13. PMID 10913192 DOI: 10.1128/Mcb.20.16.6105-6113.2000  1
2000 Ge K, Prendergast GC. Bin2, a functionally nonredundant member of the BAR adaptor gene family. Genomics. 67: 210-20. PMID 10903846 DOI: 10.1006/Geno.2000.6216  1
2000 Ge K, Minhas F, Duhadaway J, Mao NC, Wilson D, Buccafusca R, Sakamuro D, Nelson P, Malkowicz SB, Tomaszewski J, Prendergast GC. Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma. International Journal of Cancer. 86: 155-61. PMID 10738240 DOI: 10.1002/(Sici)1097-0215(20000415)86:2<155::Aid-Ijc2>3.0.Co;2-M  1
2000 Ge K, Duhadaway J, Sakamuro D, Wechsler-Reya R, Reynolds C, Prendergast GC. Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity International Journal of Cancer. 85: 376-383. PMID 10652430 DOI: 10.1002/(Sici)1097-0215(20000201)85:3<376::Aid-Ijc14>3.0.Co;2-1  1
1999 Prendergast GC, Du W. Targeting farnesyltransferase: is Ras relevant? Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 2: 81-84. PMID 11504474 DOI: 10.1054/Drup.1999.0070  1
1999 Ge K, DuHadaway J, Du W, Herlyn M, Rodeck U, Prendergast GC. Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma. Proceedings of the National Academy of Sciences of the United States of America. 96: 9689-94. PMID 10449755 DOI: 10.1073/Pnas.96.17.9689  1
1999 Duhadaway J, Rowe F, Elliott K, Mao NC, Prendergast GC. Bau, a splice form of Neurabin-I that interacts with the tumor suppressor Bin1, inhibits malignant cell transformation. Cell Adhesion and Communication. 7: 99-110. PMID 10427963 DOI: 10.3109/15419069909034394  1
1999 Elliott K, Sakamuro D, Basu A, Du W, Wunner W, Staller P, Gaubatz S, Zhang H, Prochownik E, Eilers M, Prendergast GC. Bin1 functionally interacts with Myc and inhibits cell proliferation via multiple mechanisms. Oncogene. 18: 3564-73. PMID 10380878 DOI: 10.1038/Sj.Onc.1202670  1
1999 Sakamuro D, Prendergast GC. New Myc-interacting proteins: a second Myc network emerges. Oncogene. 18: 2942-54. PMID 10378691 DOI: 10.1038/Sj.Onc.1202725  1
1999 Du W, Lebowitz PF, Prendergast GC. Elevation of alpha2(I) collagen, a suppressor of Ras transformation, is required for stable phenotypic reversion by farnesyltransferase inhibitors. Cancer Research. 59: 2059-63. PMID 10232587  1
1999 Du W, Lebowitz PF, Prendergast GC. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Molecular and Cellular Biology. 19: 1831-40. PMID 10022870 DOI: 10.1128/Mcb.19.3.1831  1
1998 Lebowitz PF, Prendergast GC. Functional interaction between RhoB and the transcription factor DB1. Cell Adhesion and Communication. 6: 277-87. PMID 9865462 DOI: 10.3109/15419069809010787  1
1998 Lebowitz PF, Prendergast GC. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene. 17: 1439-45. PMID 9779989 DOI: 10.1038/Sj.Onc.1202175  1
1998 Jensen DE, Proctor M, Marquis ST, Gardner HP, Ha SI, Chodosh LA, Ishov AM, Tommerup N, Vissing H, Sekido Y, Minna J, Borodovsky A, Schultz DC, Wilkinson KD, Maul GG, ... ... Prendergast GC, et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene. 16: 1097-112. PMID 9528852 DOI: 10.1038/Sj.Onc.1201861  1
1998 Wechsler-Reya RJ, Elliott KJ, Prendergast GC. A role for the putative tumor suppressor Bin1 in muscle cell differentiation. Molecular and Cellular Biology. 18: 566-75. PMID 9418903 DOI: 10.1128/Mcb.18.1.566  1
1997 Wechsler-Reya R, Sakamuro D, Zhang J, Duhadaway J, Prendergast GC. Structural analysis of the human BIN1 gene: Evidence for tissue-specific transcriptional regulation and alternate RNA splicing Journal of Biological Chemistry. 272: 31453-31458. PMID 9395479 DOI: 10.1074/Jbc.272.50.31453  1
1997 Sakamuro D, Sabbatini P, White E, Prendergast GC. The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene. 15: 887-98. PMID 9285684 DOI: 10.1038/Sj.Onc.1201263  1
1997 Lebowitz PF, Du W, Prendergast GC. Prenylation of RhoB is required for its cell transforming function but not its ability to activate serum response element-dependent transcription. The Journal of Biological Chemistry. 272: 16093-5. PMID 9195903 DOI: 10.1074/Jbc.272.26.16093  1
1997 Lebowitz PF, Casey PJ, Prendergast GC, Thissen JA. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. The Journal of Biological Chemistry. 272: 15591-4. PMID 9188444 DOI: 10.1074/Jbc.272.25.15591  1
1997 Lebowitz PF, Sakamuro D, Prendergast GC. Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Cancer Research. 57: 708-13. PMID 9044849  1
1996 Sakamuro D, Elliott KJ, Wechsler-Reya R, Prendergast GC. BIN1 is a novel MYC-interacting protein with features of a tumour suppressor Nature Genetics. 14: 69-77. PMID 8782822 DOI: 10.1038/Ng0996-69  1
1996 Negorev D, Riethman H, Wechsler-Reya R, Sakamuro D, Prendergast GC, Simon D. The Bin1 gene localizes to human chromosome 2q14 by PCR analysis of somatic cell hybrids and fluorescence in situ hybridization Genomics. 33: 329-331. PMID 8725406 DOI: 10.1006/Geno.1996.0205  1
1996 Negorev D, Riethman H, Wechsler-Reya R, Sakamuro D, Prendergast GC, Simon D. The Bin1 Gene Localizes to Human Chromosome 2q14 by PCR Analysis of Somatic Cell Hybrids and Fluorescence in Situ Hybridization Genomics. 33: 329-31. PMID 8660989  1
1996 Prendergast GC, Davide JP, Lebowitz PF, Wechsler-Reya R, Kohl NE. Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors Cancer Research. 56: 2626-2632. PMID 8653708  1
1995 Sakamuro D, Eviner V, Elliott KJ, Showe L, White E, Prendergast GC. c-Myc induces apoptosis in epithelial cells by both p53-dependent and p53-independent mechanisms Oncogene. 11: 2410-2418. PMID 8570193  1
1995 Lebowitz PF, Davide JP, Prendergast GC. Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. Molecular and Cellular Biology. 15: 6613-22. PMID 8524226 DOI: 10.1128/Mcb.15.12.6613  1
1995 Prendergast GC, Khosravi-Far R, Solski PA, Kurzawa H, Lebowitz PF, Der CJ. Critical role of Rho in cell transformation by oncogenic Ras. Oncogene. 10: 2289-96. PMID 7784077  1
1995 Lin HJL, Eviner V, Prendergast GC, White E. Activated H-ras rescues E1A-induced apoptosis and cooperates with E1A to overcome p53-dependent growth arrest Molecular and Cellular Biology. 15: 4536-4544. PMID 7623844 DOI: 10.1128/Mcb.15.8.4536  1
1994 Born TL, Frost JA, Schönthal A, Prendergast GC, Feramisco JR. c-Myc cooperates with activated Ras to induce the cdc2 promoter. Molecular and Cellular Biology. 14: 5710-8. PMID 8065306  1
1994 Li L, Nerlov C, Prendergast G, Macgregor D, Ziff EB. c-Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II. The Embo Journal. 13: 4070-4079. DOI: 10.1002/J.1460-2075.1994.Tb06724.X  1
1993 Omer CA, Kral AM, Diehl RE, Prendergast GC, Powers S, Allen CM, Gibbs JB, Kohl NE. Characterization of recombinant human farnesyl-protein transferase: cloning, expression, farnesyl diphosphate binding, and functional homology with yeast prenyl-protein transferases. Biochemistry. 32: 5167-76. PMID 8494894 DOI: 10.1021/Bi00070A028  1
1993 Ferré-D'Amaré AR, Prendergast GC, Ziff EB, Burley SK. Recognition by Max of its cognate DNA through a dimeric b/HLH/Z domain. Nature. 363: 38-45. PMID 8479534 DOI: 10.1038/363038A0  1
1992 Prendergast GC, Ziff EB. A new bind for Myc. Trends in Genetics : Tig. 8: 91-6. PMID 1579994 DOI: 10.1016/0168-9525(92)90196-B  1
1992 Prendergast GC, Hopewell R, Gorham BJ, Ziff EB. Biphasic effect of Max on Myc cotransformation activity and dependence on amino- and carboxy-terminal Max functions. Genes & Development. 6: 2429-39. PMID 1459463 DOI: 10.1101/Gad.6.12A.2429  1
1991 Prendergast GC, Ziff EB. Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region. Science (New York, N.Y.). 251: 186-9. PMID 1987636 DOI: 10.1126/Science.1987636  1
1991 Prendergast GC, Ziff EB. Mbh 1: a novel gelsolin/severin-related protein which binds actin in vitro and exhibits nuclear localization in vivo. The Embo Journal. 10: 757-66. PMID 1849072 DOI: 10.1002/J.1460-2075.1991.Tb08007.X  1
1991 Prendergast GC, Lawe D, Ziff EB. Association of Myn, the murine homolog of max, with c-Myc stimulates methylation-sensitive DNA binding and ras cotransformation. Cell. 65: 395-407. PMID 1840505 DOI: 10.1016/0092-8674(91)90457-A  1
1990 Prendergast GC, Diamond LE, Dahl D, Cole MD. The c-myc-regulated gene mrl encodes plasminogen activator inhibitor 1. Molecular and Cellular Biology. 10: 1265-9. PMID 2406566  1
1989 Prendergast GC, Ziff EB. DNA-binding motif. Nature. 341: 392. PMID 2507924 DOI: 10.1038/341392a0  1
1989 Prendergast GC, Cole MD. Posttranscriptional regulation of cellular gene expression by the c-myc oncogene. Molecular and Cellular Biology. 9: 124-34. PMID 2467185  1
Show low-probability matches.